EPS for Synlogic, Inc. (SYBX) Expected At $-0.56 as of March, 19

On March, 19. Investors expect Synlogic, Inc. (NASDAQ:SYBX) to announce its quarterly earnings, Zacks reports. Analysts have expectation on stock’s earnings per share of $-0.56. That’s up 24.32 % from last year’s $-0.74 earnings per share. After $-0.43 EPS report last quarter, Wall Street now predicts 30.23 % negative EPS growth of Synlogic, Inc.. SYBX touched $9 during the last trading session after $0.15 change.Currently Synlogic, Inc. is downtrending after 28.99% change in last February 27, 2018. SYBX has also 39,249 shares volume. The stock underperformed the S&P500 by 28.99%.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria.The firm is valued at $229.03 million.

For more Synlogic, Inc. (NASDAQ:SYBX) news posted briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “What’s in the Cards for Global Net Lease’s (GNL) Q4 Earnings? – Nasdaq” posted on February 26, 2019, “Piper likes OncoCyte in premarket analyst action – Seeking Alpha” on February 13, 2019, “Conagra (CAG) Divests Wesson Oil Brand, Refines Portfolio – Nasdaq” with a publish date: February 26, 2019, “Garmin (GRMN) to Report Q4 Earnings: What’s in the Offing? – Nasdaq” and the last “General Electric (GE) to Divest BioPharma, Closes Wabtec Deal – Nasdaq” with publication date: February 26, 2019.

Synlogic, Inc. (NASDAQ:SYBX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.